U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H15BrClFN4O3
Molecular Weight 457.681
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELUMETINIB

SMILES

CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO

InChI

InChIKey=CYOHGALHFOKKQC-UHFFFAOYSA-N
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

HIDE SMILES / InChI
Molecular Formula C17H15BrClFN4O3
Molecular Weight 457.681
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:23:36 UTC 2023
Edited
by admin
on Fri Dec 15 16:23:36 UTC 2023
Record UNII
6UH91I579U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELUMETINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
Systematic Name English
SELUMETINIB [MI]
Common Name English
ARRY-886
Code English
AZD6244
Code English
Selumetinib [WHO-DD]
Common Name English
selumetinib [INN]
Common Name English
AZD-6244
Code English
1H-BENZIMIDAZOLE-6-CARBOXAMIDE, 5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2- HYDROXYETHOXY)-1-METHYL-
Common Name English
SELUMETINIB [USAN]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/18/2050
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
NCI_THESAURUS C69145
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
FDA ORPHAN DRUG 475815
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
FDA ORPHAN DRUG 624017
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
FDA ORPHAN DRUG 471015
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
Code System Code Type Description
RXCUI
2289380
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
INN
9078
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID3048944
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
SMS_ID
100000124313
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
CAS
606143-52-6
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
DRUG CENTRAL
5388
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
NCI_THESAURUS
C66939
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
DAILYMED
6UH91I579U
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
USAN
XX-36
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
MERCK INDEX
m12218
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
WIKIPEDIA
SELUMETINIB
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
CHEBI
90227
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
FDA UNII
6UH91I579U
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
PUBCHEM
10127622
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
DRUG BANK
DB11689
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL1614701
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
EVMPD
SUB32237
Created by admin on Fri Dec 15 16:23:36 UTC 2023 , Edited by admin on Fri Dec 15 16:23:36 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
IN VITRO
BINDING
Structure of SELUMETINIB
EXCRETED UNCHANGED
After a single oral dose of radiolabeled selumetinib 75 mg (1.5 times the recommended dose) to healthy adults
AMOUNT EXCRETED
FECAL
CYTOCHROME P450 2E1
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
Structure of SELUMETINIB
EXCRETED UNCHANGED
After a single oral dose of radiolabeled selumetinib 75 mg (1.5 times the recommended dose) to healthy adults
AMOUNT EXCRETED
URINE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1
TARGET -> INHIBITOR
Incorporation of [J33P]phosphate from [J33P]ATP into ERK2
UNCOMPETITIVE
IC50
DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2
TARGET -> INHIBITOR
UNCOMPETITIVE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
Structure of SELUMETINIB SULFATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 2-((6-(4-BROMO-2-CHLORO-ANILINO)-7-FLUORO-3H-BENZIMIDAZOLE-5-CARBONYL)AMINO)OXYACETIC ACID
METABOLITE -> PARENT
URINE
Structure of AZ-12791138
METABOLITE -> PARENT
FECAL; URINE
Structure of 6-(4-BROMO-2-CHLORO-ANILINO)-7-FLUORO-3H-BENZIMIDAZOLE-5-CARBOXAMIDE
METABOLITE -> PARENT
FECAL
Structure of N-DESMETHYL SELUMETINIB
METABOLITE ACTIVE -> PARENT
FECAL
Structure of AZ-133266637
METABOLITE -> PARENT
FECAL; URINE
Structure of 2-((6-(4-BROMO-2-CHLORO-ANILINO)-7-FLUORO-3H-BENZIMIDAZOLE-5-CARBONYL)AMINO)OXYACETIC ACID
METABOLITE -> PARENT
PLASMA
Structure of AZ-12791138
METABOLITE -> PARENT
PLASMA
Structure of 6-(4-BROMO-2-CHLORO-ANILINO)-7-FLUORO-3H-BENZIMIDAZOLE-5-CARBOXAMIDE
METABOLITE -> PARENT
PLASMA
Structure of AZ-133266637
METABOLITE -> PARENT
PLASMA
Structure of N-DESMETHYL SELUMETINIB
METABOLITE ACTIVE -> PARENT
N-desmethyl selumetinib represents less than 10% of selumetinib levels in human plasma, but is approximately 3 to 5 times more potent than the parent compound, contributing to about 21% to 35% of the overall pharmacologic activity.
PLASMA
Structure of N-DESMETHYL SELUMETINIB
METABOLITE ACTIVE -> PARENT
URINE
Related Record Type Details
Structure of SELUMETINIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC AT STEADY-STATE

IN PEDIATRIC PATIENTS

Tmax PHARMACOKINETIC IN HEALTHY ADULTS

HIGH-FAT MEAL

SINGLE DOSE ADMINISTRATION

Volume of Distribution PHARMACOKINETIC IN PEDIATRIC PATIENTS

Tmax PHARMACOKINETIC IN HEALTHY ADULTS

SINGLE DOSE ADMINISTRATION

LOW-FAT MEAL

ORAL BIOAVAILABILITY PHARMACOKINETIC IN HEALTHY ADULTS

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966